Literature DB >> 34270765

An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.

Helen A Shih1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34270765      PMCID: PMC8563310          DOI: 10.1093/neuonc/noab179

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

1.  Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

Authors:  Jacques Grill; Birgit Geoerger; Lyle Gesner; Danuta Perek; Pierre Leblond; Adela Cañete; Isabelle Aerts; Luis Madero; Josep Sanchez de Toledo Codina; Joris Verlooy; Edward Estlin; Laura Cisar; Aurora Breazna; Andrew Dorman; Simon Bailey; Gary Nicolin; Richard G Grundy; Darren Hargrave
Journal:  Neuro Oncol       Date:  2013-07-14       Impact factor: 12.300

2.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Authors:  Giles W Robinson; Brent A Orr; Gang Wu; Sridharan Gururangan; Tong Lin; Ibrahim Qaddoumi; Roger J Packer; Stewart Goldman; Michael D Prados; Annick Desjardins; Murali Chintagumpala; Naoko Takebe; Sue C Kaste; Michael Rusch; Sariah J Allen; Arzu Onar-Thomas; Clinton F Stewart; Maryam Fouladi; James M Boyett; Richard J Gilbertson; Tom Curran; David W Ellison; Amar Gajjar
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

3.  Vismodegib.

Authors:  Charles M Rudin
Journal:  Clin Cancer Res       Date:  2012-06-07       Impact factor: 12.531

4.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

Authors:  Marcel Kool; David T W Jones; Natalie Jäger; Paul A Northcott; Trevor J Pugh; Volker Hovestadt; Rosario M Piro; L Adriana Esparza; Shirley L Markant; Marc Remke; Till Milde; Franck Bourdeaut; Marina Ryzhova; Dominik Sturm; Elke Pfaff; Sebastian Stark; Sonja Hutter; Huriye Seker-Cin; Pascal Johann; Sebastian Bender; Christin Schmidt; Tobias Rausch; David Shih; Jüri Reimand; Laura Sieber; Andrea Wittmann; Linda Linke; Hendrik Witt; Ursula D Weber; Marc Zapatka; Rainer König; Rameen Beroukhim; Guillaume Bergthold; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Sabine Schmidt; Stephan Wolf; Chris Lawerenz; Cynthia C Bartholomae; Christof von Kalle; Andreas Unterberg; Christel Herold-Mende; Silvia Hofer; Andreas E Kulozik; Andreas von Deimling; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Martin Hasselblatt; John R Crawford; Gerald A Grant; Nada Jabado; Arie Perry; Cynthia Cowdrey; Sydney Croul; Gelareh Zadeh; Jan O Korbel; Francois Doz; Olivier Delattre; Gary D Bader; Martin G McCabe; V Peter Collins; Mark W Kieran; Yoon-Jae Cho; Scott L Pomeroy; Olaf Witt; Benedikt Brors; Michael D Taylor; Ulrich Schüller; Andrey Korshunov; Roland Eils; Robert J Wechsler-Reya; Peter Lichter; Stefan M Pfister
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

5.  Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.

Authors:  Duhyeong Hwang; Taylor Dismuke; Andrey Tikunov; Elias P Rosen; John R Kagel; Jacob D Ramsey; Chaemin Lim; William Zamboni; Alexander V Kabanov; Timothy R Gershon; Marina Sokolsky-Papkov PhD
Journal:  Nanomedicine       Date:  2020-11-28       Impact factor: 5.307

6.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

7.  MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.

Authors:  Didier Frappaz; Marc Barritault; Laure Montané; Florence Laigle-Donadey; Olivier Chinot; Emilie Le Rhun; Alice Bonneville-Levard; Andreas F Hottinger; David Meyronnet; Anne-Sophie Bidaux; Gwenaële Garin; David Pérol
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

8.  L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo.

Authors:  Mingfei Zhu; Hong Wang; Chenglin Wang; Yanfen Fang; Tong Zhu; Weili Zhao; Xiaochun Dong; Xiongwen Zhang
Journal:  Front Pharmacol       Date:  2019-02-21       Impact factor: 5.810

9.  Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.

Authors:  Yuchen Li; Qingkun Song; Bryan W Day
Journal:  Acta Neuropathol Commun       Date:  2019-07-30       Impact factor: 7.801

10.  The whole-genome landscape of medulloblastoma subtypes.

Authors:  Paul A Northcott; Ivo Buchhalter; A Sorana Morrissy; Volker Hovestadt; Joachim Weischenfeldt; Tobias Ehrenberger; Susanne Gröbner; Maia Segura-Wang; Thomas Zichner; Vasilisa A Rudneva; Hans-Jörg Warnatz; Nikos Sidiropoulos; Aaron H Phillips; Steven Schumacher; Kortine Kleinheinz; Sebastian M Waszak; Serap Erkek; David T W Jones; Barbara C Worst; Marcel Kool; Marc Zapatka; Natalie Jäger; Lukas Chavez; Barbara Hutter; Matthias Bieg; Nagarajan Paramasivam; Michael Heinold; Zuguang Gu; Naveed Ishaque; Christina Jäger-Schmidt; Charles D Imbusch; Alke Jugold; Daniel Hübschmann; Thomas Risch; Vyacheslav Amstislavskiy; Francisco German Rodriguez Gonzalez; Ursula D Weber; Stephan Wolf; Giles W Robinson; Xin Zhou; Gang Wu; David Finkelstein; Yanling Liu; Florence M G Cavalli; Betty Luu; Vijay Ramaswamy; Xiaochong Wu; Jan Koster; Marina Ryzhova; Yoon-Jae Cho; Scott L Pomeroy; Christel Herold-Mende; Martin Schuhmann; Martin Ebinger; Linda M Liau; Jaume Mora; Roger E McLendon; Nada Jabado; Toshihiro Kumabe; Eric Chuah; Yussanne Ma; Richard A Moore; Andrew J Mungall; Karen L Mungall; Nina Thiessen; Kane Tse; Tina Wong; Steven J M Jones; Olaf Witt; Till Milde; Andreas Von Deimling; David Capper; Andrey Korshunov; Marie-Laure Yaspo; Richard Kriwacki; Amar Gajjar; Jinghui Zhang; Rameen Beroukhim; Ernest Fraenkel; Jan O Korbel; Benedikt Brors; Matthias Schlesner; Roland Eils; Marco A Marra; Stefan M Pfister; Michael D Taylor; Peter Lichter
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.